1222 Article Views
Publication Date: 14 May 2008
Journal: Clinical Medicine Insights: Cardiology Clinical Medicine: Cardiology 2008:2 191-200
Abstract Maria G. Barderas2, Verónica M. Dardé1,2, Fernando de la Cuesta1, Jose Luis Martin-Ventura3, Luis Miguel Blanco-Colio3, Julio Jiménez-Narcher3, Gloria Alvarez-Llamas1, Lorenzo Lopez-Bescos4, José Tuñón5, Jesús Egido3 and Fernando Vivanco1, 7
1Department of Immunology, 3Vascular Research Laboratory and 5Department of Cardiology, Fundación Jiménez Díaz, Autónoma University, Madrid; 2Vascular Pathophysiology, Hospital Nacional de Paraplejicos, SESCAM, Toledo. 4Fundación Hospital de Alcorcón. 6Hospital de Fuenlabrada. 7Proteomic Unit, Universidad Complutense, Madrid, Spain.
Abstract
We have performed a proteomic analysis of peripheral blood monocytes from ACS patients in comparison with healthy subjects and stable coronary patients in order to search novel biomarkers of ACS in circulating monocytes. Monocytes were isolated from blood of patients with non-ST elevation ACS (n = 27) at day 0, 2 and 6 months, and from patients with stable coronary disease (n = 10) and matched healthy controls (n = 11). The proteomic analysis of monocytes from ACS patients at day 0 showed that cathepsin D is differentially expressed compared to healthy subjects and stable coronary patients. Western blot analysis indicated that the mature form of cathepsin D at day 0 was overexpressed in monocytes of ACS patients in relation to healthy subjects. In contrast, the precursor of this enzyme, absent at day 0 in ACS patients, was highly expressed in monocytes of healthy subjects. Furthermore, the upregulation of the mature form of cathepsin D diminished along the time, while the expression of the precursor increased. ACS patients also showed significantly increased plasma cathepsin D levels on admission compared to healthy subjects and stable patients. Cathepsin D plasma levels diminished at 2 and 6 months to control values. Finally, cathepsin D levels were independent of the existence of coronary risk factors and CRP levels, correlating only with CD40L. Since this protease participates in the genesis and rupture of atherosclerotic plaques, it could represent a potential marker of ACS.
Discussion
No comments yet...Be the first to comment.
I had an excellent experience publishing our review article in Clinical Medicine Reviews. The managing editor was very helpful and the process was very timely and transparent.Professor Jonathan A. Bernstein (University of Cincinnati College of Medicine, Division of Immunology, Allergy Section, Cincinnati, OH, USA) What our authors say
Copyright © 2010 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)